Selective Inhibition of Bruton’s Tyrosine Kinase by a Designed Covalent Ligand Leads to Potent Therapeutic Efficacy in Blood Cancers Relative to Clinically Used InhibitorsBárbara B. Sousa, Gonçalo J. L. Bernardes|ACS Pharmacology & Translational Science|2022Cited by 9